

Date: 14 March 2022

Re: Freedom of Information Request
Ref: 41-2022

Thank you for your email dated the 15/2/2022, requesting information in relation to treatment of renal cell carcinoma.

The information that you require is as follows:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- **Avelumab + Axitinib 104**
- **Axinitib 27**
- **Cabozantinib 117**
- **Everolimus 2**
- **Lenvatinib + Everolimus 0**
- **Nivolumab 117**
- **Nivolumab + Ipilimumab 0**
- **Pazopanib 3**
- **Pembrolizumab + Axitinib 0**
- **Pembrolizumab monotherapy 0**
- **Sunitinib 0**
- **Temsirolimus 0**
- **Tivozanib 63**
- **Other active systemic anti-cancer therapy [Please see table below](#)**

Other	Number of patients
AVELUMAB	9
Denosumab	55
Lenvatinib	29
OP EVEROLIMUS (5MG)	25
RAMPART-DURVALUMAB	14

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib **0**
- Dabrafenib **3**
- Dabrafenib AND Trametinib **41**
- Encorafenib AND Binimetinib **4**
- Ipilimumab **4**
- Ipilimumab AND Nivolumab **0**
- Nivolumab **165**
- Pembrolizumab **247**
- Trametinib **4**
- Vemurafenib **0**
- Vemurafenib AND Cobimetinib **0**
- Other active systemic anti-cancer therapy [Please see table below](#)
- Palliative care only **54**

Other	Number of patients
BINIMETINIB	3
Binimetinib + Encorafenib	4
DABRAFENIB TRAMETINIB	4
Denosumab	7
ENCORAFENIB	4
EVEROLIMUS	1
IMCGP100 202-IMCgp100	13
OP DABRAFENIB	7
REPLIMUNE2-RP2	13
REPLIMUNE-NIVOLUMAB	23
REPLIMUNE-RP1	9

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- Cobimetinib **0**
- Dabrafenib **3**
- Dabrafenib AND Trametinib **0**
- Encorafenib AND Binimetinib **0**
- Ipilimumab **6**
- Ipilimumab AND Nivolumab **0**
- Nivolumab **13**
- Pembrolizumab **15**
- Trametinib **0**
- Vemurafenib **0**
- Vemurafenib AND Cobimetinib **0**
- Other active systemic anti-cancer therapy [Please see table below](#)

- Palliative care only 1

Other	Number of patients
REPLIMUNE-NIVOLUMAB	5
REPLIMUNE-RP1	5

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

The Clatterbridge Cancer Centre NHS Foundation Trust do not provide surgery.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

Margaret Moore
Information Governance Administrator
Contact Email: ccf-tr.foi@nhs.net